降脂药物运用于结直肠癌治疗中的研究进展

doi:10.12677/acm.2026.1672757

期刊菜单

降脂药物运用于结直肠癌治疗中的研究进展
Research Progress on the Application of Lipid-Lowering Drugs in the Treatment of Colorectal Cancer

DOI: 10.12677/acm.2026.1672757, PDF,
作者: 公绪宁, 张赟政, 徐广懋, 杨振, 刘建刚：山东第一医科大学第二附属医院胃肠外科，山东泰安；陶鸽如：山东第一医科大学天外村校区中心实验室，山东泰安
关键词: 结直肠癌；降脂药物；他汀类药物；胆固醇；脂肪酸；Colorectal Cancer； Lipid-Lowering Drugs； Statins； Cholesterol； Fatty Acids

摘要: 结直肠癌(Colorectal cancer, CRC)是十分常见且研究充分的肠道上皮源性恶性肿瘤，但目前其发病机制尚未完全厘清。已有明确的证据表明，CRC的发生发展必然伴随着肿瘤脂质代谢的异常，即多种酶、蛋白质及信号分子表达失调，进而通过促进脂质摄取、合成及脂滴蓄积诸种方式促进CRC增殖、生长及转移。因此，干预脂质代谢已经成为CRC治疗的新方向。他汀类药物、前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂及依折麦布等降脂药物能直接、有效地降低体内胆固醇及脂肪酸水平，从而抑制CRC的生长、增殖及转移。故而本文对CRC中脂质代谢异常的特征及降脂药物的抗肿瘤作用做系统、有逻辑性的综述，也由此自然地引出对CRC临床治疗的新思路。

Abstract: Colorectal cancer (CRC) is a highly prevalent and extensively investigated malignant tumor originating from intestinal epithelium; nevertheless, its pathogenesis has not yet been fully elucidated. Accumulating solid evidence has confirmed that the initiation and progression of CRC are invariably accompanied by aberrant tumor lipid metabolism. Specifically, dysregulated expression of multiple enzymes, proteins and signaling molecules facilitates lipid uptake, de novo lipid synthesis and lipid droplet accumulation, thereby promoting proliferation, growth and metastasis of CRC cells. Accordingly, intervening lipid metabolism has emerged as a novel therapeutic strategy for CRC treatment. Lipid-lowering agents, including statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and ezetimibe, can directly and effectively reduce systemic cholesterol and fatty acid levels, and further suppress the growth, proliferation and metastasis of CRC. This article therefore systematically and logically reviews the characteristics of abnormal lipid metabolism in CRC as well as the anti-tumor effects of lipid-lowering drugs, aiming to provide novel insights for the clinical management of CRC.

文章引用：公绪宁, 张赟政, 徐广懋, 杨振, 刘建刚, 陶鸽如. 降脂药物运用于结直肠癌治疗中的研究进展[J]. 临床医学进展, 2026, 16(7): 2279-2287. https://doi.org/10.12677/acm.2026.1672757

参考文献

[1]	Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[2]	Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., et al. (2021) Contradictory Roles of Lipid Metabolism in Immune Response within the Tumor Microenvironment. Journal of Hematology & Oncology, 14, Article No. 187. https://doi.org/10.1186/s13045-021-01200-4
[3]	Hassanabad, A.F. (2019) Current Perspectives on Statins as Potential Anti-Cancer Therapeutics: Clinical Outcomes and Underlying Molecular Mechanisms. Translational Lung Cancer Research, 8, 692-699. https://doi.org/10.21037/tlcr.2019.09.08
[4]	Pascual, G., Avgustinova, A., Mejetta, S., Martín, M., Castellanos, A., Attolini, C.S., et al. (2016) Targeting Metastasis-Initiating Cells through the Fatty Acid Receptor CD36. Nature, 541, 41-45. https://doi.org/10.1038/nature20791
[5]	Nath, A., Li, I., Roberts, L.R. and Chan, C. (2015) Elevated Free Fatty Acid Uptake via CD36 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Scientific Reports, 5, Article No. 14752. https://doi.org/10.1038/srep14752
[6]	Geng, F., Cheng, X., Wu, X., Yoo, J.Y., Cheng, C., Guo, J.Y., et al. (2016) Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis. Clinical Cancer Research, 22, 5337-5348. https://doi.org/10.1158/1078-0432.ccr-15-2973
[7]	Koizume, S. and Miyagi, Y. (2016) Lipid Droplets: A Key Cellular Organelle Associated with Cancer Cell Survival under Normoxia and Hypoxia. International Journal of Molecular Sciences, 17, Article 1430. https://doi.org/10.3390/ijms17091430
[8]	Snaebjornsson, M.T., Janaki-Raman, S. and Schulze, A. (2020) Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. Cell Metabolism, 31, 62-76. https://doi.org/10.1016/j.cmet.2019.11.010
[9]	Jeon, Y.G., Kim, Y.Y., Lee, G. and Kim, J.B. (2023) Physiological and Pathological Roles of Lipogenesis. Nature Metabolism, 5, 735-759. https://doi.org/10.1038/s42255-023-00786-y
[10]	Wei, W., Qin, B., Wen, W., Zhang, B., Luo, H., Wang, Y., et al. (2023) Fbxw7β Loss-of-Function Enhances Fasn-Mediated Lipogenesis and Promotes Colorectal Cancer Growth. Signal Transduction and Targeted Therapy, 8, Article No. 187. https://doi.org/10.1038/s41392-023-01405-8
[11]	Cao, D., Song, X., Che, L., Li, X., Pilo, M.G., Vidili, G., et al. (2017) Both de Novo Synthetized and Exogenous Fatty Acids Support the Growth of Hepatocellular Carcinoma Cells. Liver International, 37, 80-89. https://doi.org/10.1111/liv.13183
[12]	Huang, S., Rutkowsky, J.M., Snodgrass, R.G., Ono-Moore, K.D., Schneider, D.A., Newman, J.W., et al. (2012) Saturated Fatty Acids Activate TLR-Mediated Proinflammatory Signaling Pathways. Journal of Lipid Research, 53, 2002-2013. https://doi.org/10.1194/jlr.d029546
[13]	Zhu, X., Ying, X., Liu, Y. et al. (2024) Stability and Variability of Molecular Subtypes: Comparative Analysis of Primary and Metastatic Triple-Negative Breast Cancer. Cancer Biology and Medicine, 21, 784-798.
[14]	Feng, W.W., Zuppe, H.T. and Kurokawa, M. (2023) The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target. Cells, 12, Article 1605. https://doi.org/10.3390/cells12121605
[15]	Xia, L., Zhou, Z., Chen, X., Luo, W., Ding, L., Xie, H., et al. (2023) Ligand-Dependent CD36 Functions in Cancer Progression, Metastasis, Immune Response, and Drug Resistance. Biomedicine & Pharmacotherapy, 168, Article 115834. https://doi.org/10.1016/j.biopha.2023.115834
[16]	Glaviano, A., Foo, A.S.C., Lam, H.Y., Yap, K.C.H., Jacot, W., Jones, R.H., et al. (2023) PI3K/AKT/mTOR Signaling Transduction Pathway and Targeted Therapies in Cancer. Molecular Cancer, 22, Article No. 138. https://doi.org/10.1186/s12943-023-01827-6
[17]	Liu, T., Peng, F., Yu, J., Tan, Z., Rao, T., Chen, Y., et al. (2019) LC-MS-Based Lipid Profile in Colorectal Cancer Patients: Tags Are the Main Disturbed Lipid Markers of Colorectal Cancer Progression. Analytical and Bioanalytical Chemistry, 411, 5079-5088. https://doi.org/10.1007/s00216-019-01872-5
[18]	Kondo, Y., Nishiumi, S., Shinohara, M., Hatano, N., Ikeda, A., Yoshie, T., et al. (2011) Serum Fatty Acid Profiling of Colorectal Cancer by Gas Chromatography/Mass Spectrometry. Biomarkers in Medicine, 5, 451-460. https://doi.org/10.2217/bmm.11.41
[19]	Zhang, J., Zhang, L., Ye, X., Chen, L., Zhang, L., Gao, Y., et al. (2013) Characteristics of Fatty Acid Distribution Is Associated with Colorectal Cancer Prognosis. Prostaglandins, Leukotrienes and Essential Fatty Acids, 88, 355-360. https://doi.org/10.1016/j.plefa.2013.02.005
[20]	Jiang, W., Jin, W. and Xu, A. (2024) Cholesterol Metabolism in Tumor Microenvironment: Cancer Hallmarks and Therapeutic Opportunities. International Journal of Biological Sciences, 20, 2044-2071. https://doi.org/10.7150/ijbs.92274
[21]	Vander Heiden, M.G., Cantley, L.C. and Thompson, C.B. (2009) Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science, 324, 1029-1033. https://doi.org/10.1126/science.1160809
[22]	Luo, M., Yan, J., Hu, X., Li, H., Li, H., Liu, Q., et al. (2023) Targeting Lipid Metabolism for Ferroptotic Cancer Therapy. Apoptosis, 28, 81-107. https://doi.org/10.1007/s10495-022-01795-0
[23]	Ma, Y., Temkin, S.M., Hawkridge, A.M., Guo, C., Wang, W., Wang, X., et al. (2018) Fatty Acid Oxidation: An Emerging Facet of Metabolic Transformation in Cancer. Cancer Letters, 435, 92-100. https://doi.org/10.1016/j.canlet.2018.08.006
[24]	Harly, C., Joyce, S.P., Domblides, C., Bachelet, T., Pitard, V., Mannat, C., et al. (2021) Human γδ T Cell Sensing of AMPK-Dependent Metabolic Tumor Reprogramming through TCR Recognition of EphA2. Science Immunology, 6, eaba9010. https://doi.org/10.1126/sciimmunol.aba9010
[25]	Tang, W., Li, G., Lin, Q., Zhu, Z., Wang, Z. and Wang, Z. (2023) Multiplex Immunohistochemistry Defines Two Cholesterol Metabolism Patterns Predicting Immunotherapeutic Outcomes in Gastric Cancer. Journal of Translational Medicine, 21, Article No. 887. https://doi.org/10.1186/s12967-023-04758-4
[26]	Wang, Z., Zhang, L., Wan, Z., He, Y., Huang, H., Xiang, H., et al. (2018) Atorvastatin and Caffeine in Combination Regulates Apoptosis, Migration, Invasion and Tumorspheres of Prostate Cancer Cells. Pathology & Oncology Research, 26, 209-216. https://doi.org/10.1007/s12253-018-0415-7
[27]	Wang, C., Li, P., Xuan, J., Zhu, C., Liu, J., Shan, L., et al. (2017) Cholesterol Enhances Colorectal Cancer Progression via ROS Elevation and MAPK Signaling Pathway Activation. Cellular Physiology and Biochemistry, 42, 729-742. https://doi.org/10.1159/000477890
[28]	Balijepalli, P., Sitton, C.C. and Meier, K.E. (2021) Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA so Special? Cells, 10, Article 2059. https://doi.org/10.3390/cells10082059
[29]	Wang, S., Chen, J. and Guo, X. (2022) KAI1/CD82 Gene and Autotaxin-Lysophosphatidic Acid Axis in Gastrointestinal Cancers. World Journal of Gastrointestinal Oncology, 14, 1388-1405. https://doi.org/10.4251/wjgo.v14.i8.1388
[30]	Leve, F., Peres-Moreira, R.J., Binato, R., Abdelhay, E. and Morgado-Díaz, J.A. (2015) LPA Induces Colon Cancer Cell Proliferation through a Cooperation between the ROCK and STAT-3 Pathways. PLOS ONE, 10, e0139094. https://doi.org/10.1371/journal.pone.0139094
[31]	Yang, M.H., Rampal, S., Sung, J., Choi, Y., Son, H.J., Lee, J.H., et al. (2013) The Association of Serum Lipids with Colorectal Adenomas. American Journal of Gastroenterology, 108, 833-841. https://doi.org/10.1038/ajg.2013.64
[32]	Niso‐Santano, M., Malik, S.A., Pietrocola, F., Bravo‐San Pedro, J.M., Mariño, G., Cianfanelli, V., et al. (2015) Unsaturated Fatty Acids Induce Non‐Canonical Autophagy. The EMBO Journal, 34, 1025-1041. https://doi.org/10.15252/embj.201489363
[33]	Berger, E., Nassra, M., Atgié, C., Plaisancié, P. and Géloën, A. (2017) Oleic Acid Uptake Reveals the Rescued Enterocyte Phenotype of Colon Cancer Caco-2 by HT29-MTX Cells in Co-Culture Mode. International Journal of Molecular Sciences, 18, Article 1573. https://doi.org/10.3390/ijms18071573
[34]	Beckwitt, C.H., Brufsky, A., Oltvai, Z.N. and Wells, A. (2018) Statin Drugs to Reduce Breast Cancer Recurrence and Mortality. Breast Cancer Research, 20, Article No. 144. https://doi.org/10.1186/s13058-018-1066-z
[35]	Cruz, P.M.R., Mo, H., McConathy, W.J., Sabnis, N. and Lacko, A.G. (2013) The Role of Cholesterol Metabolism and Cholesterol Transport in Carcinogenesis: A Review of Scientific Findings, Relevant to Future Cancer Therapeutics. Frontiers in Pharmacology, 4, Article ID: 118. https://doi.org/10.3389/fphar.2013.00119
[36]	Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C. and Hermoso, M.A. (2014) Chronic Inflammation and Cytokines in the Tumor Microenvironment. Journal of Immunology Research, 2014, 1-19. https://doi.org/10.1155/2014/149185
[37]	Amin, F., Fathi, F., Reiner, Ž., Banach, M. and Sahebkar, A. (2022) The Role of Statins in Lung Cancer. Archives of Medical Science, 18, 141-152. https://doi.org/10.5114/aoms/123225
[38]	Selvin, T., Berglund, M., Lenhammar, L., Jarvius, M., Nygren, P., Fryknäs, M., et al. (2023) Phenotypic Screening Platform Identifies Statins as Enhancers of Immune Cell-Induced Cancer Cell Death. BMC Cancer, 23, Article No. 164. https://doi.org/10.1186/s12885-023-10645-4
[39]	Jalving, M., Koornstra, J.J., de Jong, S., de Vries, E.G.E. and Kleibeuker, J.H. (2005) Review Article: The Potential of Combinational Regimen with Non‐Steroidal Anti‐Inflammatory Drugs in the Chemoprevention of Colorectal Cancer. Alimentary Pharmacology & Therapeutics, 21, 321-339. https://doi.org/10.1111/j.1365-2036.2005.02335.x
[40]	Xiao, H., Zhang, Q., Lin, Y., Reddy, B.S. and Yang, C.S. (2008) Combination of Atorvastatin and Celecoxib Synergistically Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Cells. International Journal of Cancer, 122, 2115-2124. https://doi.org/10.1002/ijc.23315
[41]	Kwon, R.J., Park, E., Lee, S.Y., Lee, Y., Hwang, C., Kim, C., et al. (2021) Expression and Prognostic Significance of Niemann-Pick C1-Like 1 in Colorectal Cancer: A Retrospective Cohort Study. Lipids in Health and Disease, 20, Article No. 104. https://doi.org/10.1186/s12944-021-01539-0
[42]	Zheng, Y., Yang, W., Jia, Y., Ji, J., Wu, L., Feng, J., et al. (2023) Promotion of Colorectal Cancer Cell Death by Ezetimibe via mTOR Signaling-Dependent Mitochondrial Dysfunction. Frontiers in Pharmacology, 14, Article ID: 1081980. https://doi.org/10.3389/fphar.2023.1081980
[43]	Solomon, K.R., Pelton, K., Boucher, K., Joo, J., Tully, C., Zurakowski, D., et al. (2009) Ezetimibe Is an Inhibitor of Tumor Angiogenesis. The American Journal of Pathology, 174, 1017-1026. https://doi.org/10.2353/ajpath.2009.080551
[44]	Yang, K., Zhu, J., Luo, H., Yu, S. and Wang, L. (2021) Pro-Protein Convertase Subtilisin/Kexin Type 9 Promotes Intestinal Tumor Development by Activating Janus Kinase 2/Signal Transducer and Activator of Transcription 3/SOCS3 Signaling in Apc^Min^/+ Mice. International Journal of Immunopathology and Pharmacology, 35.

为你推荐

友情链接